Mr. Tony O'Brien:

As a matter of general principle, we are always open to further engagement with any pharmaceutical company beyond the end of an initial process. My answer - I will give the Deputy full details - is that this has been determined on the grounds of the clinical benefit derived or provided by the medication concerned.